linjc16/ctgov huggingface dataset:
B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression

Study Overview
=================
Brief Summary
-----------------
B type chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the western world. It is a disease that occurs primarily in aging individuals and occurs more frequently in males than females. Although B-CLL was considered a homogeneous condition, recent studies by our laboratory and others suggest that B-CLL cases can be divided into two subgroups. These sub-groups can be identified by either the presence or the absence of mutations in antibody genes and/or by the percentage of B-CLL cells expressing a particular protein called CD38. These two sub-groups (unmutated antibody genes high percent CD38 and mutated antibody genes low percentage CD38) follow strikingly clinically different courses. For example, the unmutated/CD38+ group experiences a much more aggressive disease and these patients almost invariably die much sooner than the cases in the other group. In addition, the patients in the mutated CD38+ group require much more chemotherapy than mutatedlCD38-. Finally, surprisingly there is a much higher representation of males in the poor outcome unmutated CD38 group than in the better outcome group. The reasons for these differences in clinical outcome and gender bias are unknown.

Official Title
-----------------
B-CLL Subgroups: Maturation Stage and Gene Expression

Conditions
-----------------
Chronic Lymphocytic Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age, Patients must be able to contribute the required amount of blood without compromising their well being, Participants must be willing to be contacted again in the future for additional blood drawing. Exclusion Criteria: Patients who are known to be anemic, with a hemoglobin < 8, Patients who are known to be infected with HIV.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic Lymphocytic Leukemia<br>Chronic Lymphocytic Leukemia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| differentiating B-CLL cells by the presence or absence of mutations in antibody genes and/or by the percentage of cells expressing CD38 and the difference in clinical disease course and outcome for each group |  | follow through the clinical disease course for each group | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Lymphocytic Leukemia
Save Hearts in Arizona Registry and Education (SHARE) Project

Study Overview
=================
Brief Summary
-----------------
Evaluation of the impact of bystander CPR, prehospital resuscitation protocols, and hospital post-resuscitation protocols for out-of-hospital cardiac arrest patients in the state of Arizona.

Conditions
-----------------
Out-of-hospital Cardiac Arrest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Out of Hospital Cardiac Arrest (loss of spontaneous circulation and EMS attempted resuscitation) Exclusion Criteria: Do Not Resuscitate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Resuscitation of OHCA<br>Resuscitation of out-of-hospital cardiac arrest | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival to hospital discharge | Patients will be followed for the duration of hospital stay. The average time from admission to either discharge or death is expected to be approximately 2 weeks. | Upon hospital discharge and annually up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Emergency Medical Services Cardiopulmonary Resuscitation (CPR) quality | Chest compression depth, rate, recoil, fraction. Patients will be followed for the duration of prehospital resuscitation. The average timeframe is expected to be approximately 15 minutes. | Prehospital resuscitation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac arrest, CPR, resuscitation
Ultrasound Guided Subclavian Vein Cannulation at Emergency Room

Study Overview
=================
Brief Summary
-----------------
To observe and report the success rate associated with the use of ultrasound for subclavian vein catheterization. To observe and report the type and complications and any constrains associated with this technique.

Detailed Description
-----------------
Central venous catheterisation is a commonly performed procedure in anaesthesia, critical care, acute and emergency medicine. 1 , the subclavian vein (SCV) has been an important vessel for central venous cannulation.2 The SCV cannulation offers several advantages when compared to the common alternative sites for central venous access. These advantages may include fewer cases of thrombosis, infectious complications, better patient comfort, and increased ability to remain patent in hypovolemic states.3-4 Traditionally, subclavian venous catheterisation has been performed using the landmark technique and because of the complications associated with this technique, it is not commonly performed.1 the complications such as catheter malposition, arterial puncture, hematoma, pneumothorax, hemothorax, and nerve injury.

Official Title
-----------------
Ultrasound Guided Subclavian Vein Cannulation at Emergency Room , Success Rate and Incidence of Complications

Conditions
-----------------
Ultrasound Subclavian Cannulation

Intervention / Treatment
-----------------
* Device: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patient admitted to emergency room and indicated for central venous catheterization Exclusion Criteria: 1. Any contraindication for central vein cannulation as coagulopathy, hemorrhage from target vessel, suspected proximal vascular injury 2- Age below 18 year

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Ultrasound|Use of ultrasound at subclavian vein cannulation for visualization|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| success rate of the ultrasound guided subclavian vein cannulation success rate of the ultrasound guided subclavian vein cannulation Success rate of ultrasound guided of subclavian vein cannulation | Use of ultrasound at visualization of cannulation of subclavian vein | Baseline |
High-flow Nasal Cannula Oxygen Therapy for Ischemic Stroke Patients With Dysphagia and Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
High flow nasal cannula (HFNC) ventilation therapy was found to improve the severity of obstructive sleep apnea in non-stroke subjects. The investigators hypothesized that HFNC might be effective in stroke patients with dysphagia who needed nasogastric tube feeding and can not receive continuous positive airway pressure ventilation for obstructive sleep apnea.

Official Title
-----------------
High-flow Nasal Cannula Oxygen Therapy for Ischemic Stroke Patients With Dysphagia and Obstructive Sleep Apnea

Conditions
-----------------
Cerebral Infarction, Sleep Apnea, Obstructive, Deglutition Disorders

Intervention / Treatment
-----------------
* Device: high flow nasal cannula ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ischemic stroke patients with dysphagia and obstructive sleep apnea who need nasogastric tube feedings Exclusion Criteria: congestive heart failure, unconsciousness, chronic obstructive pulmonary disease, intracranial hemorrhage or malignancy, and unstable medical and neurological conditions central sleep apnea

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HFNC<br> | Device: high flow nasal cannula ventilation<br>* High-flow nasal cannula (HFNC) ventilation therapy: supply heated & humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| apnea-hypopnea index | respiratory inductance plethysmography sum (RIPsum) without calibration to score apnea and hypopnea events (American Academy of Sleep Medicine alternative criteria) | once at polysomnography study night when receive high flow nasal cannula titration study | 
| oxyhemoglobin desaturation index | number of times per hour of sleep that the blood's oxygen saturation level drops by ≥ 3% from baseline | once at polysomnography study night when receive high flow nasal cannula titration study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulse wave velocity | velocity (m/s) measured by SphygmoCor CPV system | baseline and 1 week after high flow nasal cannula therapy | 
| heart rate variability | measured by QHRV system (Medeia Ltd.) | baseline and 1 week after high flow nasal cannula therapy |
Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards

Study Overview
=================
Brief Summary
-----------------
End-stage renal disease (ESRD) is a healthy, social and economic threat worldwide. In the past ten years, the incidence and prevalence of ESRD patients have tremendously increased, ranking at the top in the world. The reasons for such high incidence and prevalence are multifactor. Early diagnosis and closed monitor of the patients with chronic kidney disease (CKD) may be beneficial, but not confirmed yet.The advising mechanisms for non-doing or withdraw long-term dialysis. All these studies will be performed in a multicentered project. Three medical centers in which CKD researches have been conducted for many years will provide a large cohort and share the data collected from their own hospitals. We expect that the results will provide an excellent guideline for CKD care, achieve cost-effectiveness of dialysis therapy and better life quality of ESRD patients.

Detailed Description
-----------------
Purpose: Development of early diagnostic techniques and setup of local therapeutic guidelines and standards. Design: The group plans to host the co-operation of hospitals, based on the geographical distribution of co-operation of several hospitals to choose the renal physician interviews the doctor and patient received a total of 30 objects was conducted qualitative in-depth interviews. Time:2008/9/1 2011/8/31 Inclusion criteria): To withdraw from dialysis treatment of chronic kidney disease, qualitative research, to-depth interviews, field observation, video recording, and public hospitals at the same time the collection of literature.

Official Title
-----------------
Prevention and Treatment of Chronic Kidney Disease in Taiwan - Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic kidney disease patients with the end of dialysis to withdrawal.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hemodialysis patients, Kidney, Physician attitudes, Family wishes, 30 numbers require maximum
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.

Study Overview
=================
Brief Summary
-----------------
This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.

Official Title
-----------------
ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Other: ALK Inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients should be histologically diagnosed with metastatic colorectal cancer or postoperative recurrence; Patients with ALK mutation(including mutation, fusion, rearrangements ); Patients have measurable lesions; Patients are not available for targeted therapy or patients refuse to receive targeted therapy afer second-line treatment; Over 3 weeks after radiotherapy and the radiotherapy focus was not be measured; Age should be 18-25 years; Performance status should be 0-2; Life expectancy should be more than 12 weeks; Exclusion Criteria: Patients underwented major surgery or severe trauma within 4 weeks; Patients allergiced to experimental drugs; Patient ready to give birth or who is pregnant; Patients with brain metastases; Patients with chemotherapy contraindication; Patients could not tolerate chemotherapy; Patients have secondary primary tumor.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ALK mutation<br> | Other: ALK Inhibitor<br>* Any ALK inhibitor like crizotinib, alectinib and so on.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Respone Rate(ORR) | Evaluation of tumor burden based on RECIST criteria every 2 month. | up to 36months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ALK mutation, ALK inhibitor, Metastatic Colorectal Cancer
Pulse Oximetry Measurement and Transfusions

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this observational study was to determine if pRBC transfusions decrease the frequency of intermittent hypoxia events in very low birth weight infants (VLBW) during the first six weeks of life. The impact on non-pRBC transfusions on the frequency of intermittent hypoxia was also assessed.

Official Title
-----------------
Effect of Blood Transfusions on Intermittent Hypoxic Episodes in Very Low Birth Weight Infants

Conditions
-----------------
Hypoxia Neonatal, Premature, Blood Transfusion

Intervention / Treatment
-----------------
* Other: Transfusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 23+0 to 28+6 weeks gestational age at birth Exclusion Criteria: Infants with life-limiting diagnoses Cyanotic heart disease In utero fetal transfusion Twin to twin transfusion syndrome Isoimmune hemolytic disease Severe acute hemorrhage Acute shock Sepsis with coagulopathy Need for perioperative transfusion Parents opposed to transfusion of blood Parents with hemoglobinopathy or congenital anemia

Ages Eligible for Study
-----------------
Maximum Age: 6 Weeks

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transfusion<br> | Other: Transfusion<br>* pRBC and non-pRBC transfusions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in number of Intermittent hypoxia | An intermittent hypoxemia event is defined as a fall in oxygen saturations to less than 80% for >/= 10 secs and <3 minutes with a minimal time interval of 4 seconds between events. | Change in number of intermittent hypoxia before (approximately 8 hours) and after transfusion (approximately 8 hours). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoxia | Percent time with oxygen saturations less than 85%, 80% and 75%. | 8 hours prior to transfusion and 8 hours after transfusion. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transfusion, Intermittent hypoxia
In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy

Study Overview
=================
Brief Summary
-----------------
Clinical in vivo confocal microscopy (IVCM) is a relatively new technique of corneal evaluation that permits non-invasive imaging of corneal structures on the cellular level. Precise anatomic characterization of corneal structures, including corneal nerves, can be rapidly performed with high resolution.

Detailed Description
-----------------
Evaluation of the corneal nerve layer with IVCM provides a method of direct visualization of peripheral small fiber nerves and a quantifiable assessment of nerve abnormalities in a low risk, non-invasive manner. Therefore, our goal is to develop a non-invasive diagnostic protocol as a quantitative tool for the evaluation of DPN. The protocol and the tool we seek to develop could ultimately be used in large-scale clinical trials and in clinical practice to assess DPN severity and progression. We hypothesize that in vivo confocal imaging of the corneal nerve layer is a clinically viable method to assess and quantify systemic peripheral nerve health. We emphasize that this imaging method can be used in both humans and animal models to provide quantifiable, longitudinal data on the same live individual to advance our understanding of the development and progression of DPN, and to evaluate treatment effectiveness.

Official Title
-----------------
In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy

Conditions
-----------------
Diabetic Peripheral Neuropathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetes Exclusion Criteria: history of laser eye surgery, corneal disease, multiple sclerosis, Parkinson's disease, or any known systemic neuropathy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| None to Mild<br>Subjects with Diabetes with none to mild peripheral neuropathy | |
| Severe<br>Subjects with diabetes with severe neuropathy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes between control and diabetic patients |  | 12 years |
Antimicrobial Pulpotomy of Primary Molars

Study Overview
=================
Brief Summary
-----------------
There is a lack of evidence of the long-term successful outcomes of antimicrobial endodontic treatment for primary teeth. This study intended to evaluate (by survival analysis) the effectiveness of an antimicrobial pulpotomy (chloramphenicol, tetracycline, zinc oxide/eugenol) in primary molars compared to calcium hydroxide pulpectomy, testing the hypothesis that antimicrobial pulpotomy could be an alternative pulp therapy for primary teeth with pulp inflammation or necrosis.

Official Title
-----------------
Survival of Primary Molars Treated With Antimicrobial Pulpotomy or Calcium Hydroxide Pulpectomy

Conditions
-----------------
Inflammation, Necrosis

Intervention / Treatment
-----------------
* Procedure: Antimicrobial pulpotomy
* Procedure: Calcium hydroxide pulpectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children (ASA PS 1) Children presenting one or more primary molar with pulp inflammation or necrosis due to carious lesion and indicated for endodontic therapy Exclusion Criteria: Lost to follow-up
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Antimicrobial pulpotomy<br>Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste | Procedure: Antimicrobial pulpotomy<br>* Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.<br>* Other names: Non-vital pulpotomy;|
| Active Comparator: Calcium hydroxide pulpectomy<br>Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication | Procedure: Calcium hydroxide pulpectomy<br>* Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulpotomy, pulpectomy, primary teeth, dental care for children